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MetaflammationA B S T R A C T
Aim: Cardiovascular disease (CVD) is prevalent in women after menopause, which may be
associated with obesity, insulin resistance and metaflammation. Despite the recognized
role of immunological mechanisms in vascular remodeling, the role of dendritic cells
(DCs) is still unclear. The aim was to characterize monocyte-derived DCs (Mo-DC) in
post-menopausal patients with type 2 diabetes (T2DM) and obese woman, without clinical
manifestations of atherosclerosis.
Methods: Obese post-menopausal women with or without T2DM were enrolled and were
compared to age-matched healthy women. DCs obtained from patients were phenotypi-
cally and functionally characterized by flow cytometry and mixed lymphocyte reaction.
MRNA integrins expression was assessed by real time RT-PCR; circulating fetuin-A and adi-
ponectin levels were measured by ELISA.
Results: Phenotypic dysregulation of Mo-DC reported was related to a defective allogenic
lymphocyte stimulation and to an increased mRNA of CD11c, CD18 and DC-SIGN/CD209
which regulate their adhesion to vascular wall cells. Fetuin-A and adiponectin levels were
significantly altered and negatively correlated. Hyperglycaemia significantly impaired
CD14+ transdifferentiation into Mo-DC.
Conclusions: These data show a dysfunction of Mo-DCs obtained from precursors isolated
from T2DM obese post-menopausal woman without any documented clinical CV event.
Association of obesity to diabetes seems to worsen DC’s phenotype and function and
increase vascular inflammation.
 2020 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY
license (http://creativecommons.org/licenses/by/4.0/).1. Introduction
Obesity and Type 2 diabetes mellitus (T2DM) are considered
two chronic low-grade inflammatory illnesses [1]. Accordingto World Health Organization, about 13% and 8% of world’s
adult population suffers of obesity or T2DM, respectively, with
87.5% of T2DM patients that are obese or overweight.
Both conditions represent independent risk factors forf Florence,
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during the reproductive period, is lower compared to men.
After the loss of estrogen protection [2], gender differences
in CVD risk fade. However mortality for cardiovascular events
is lower in females of any age class [3].
Clinical and preclinical data highlight the role of adipose
tissue and insulin resistance in the development of a sys-
temic inflammatory state. Among several pathways
involved, impaired adipokine and hepatokine levels are
reported [4]. Adiponectin and fetuin-A seem to have an
important role. Adiponectin plays a major role in glucose
and lipid metabolism, it has important metabolic and anti-
inflammatory actions with a protective role in T2DM devel-
opment [5]. Fetuin-A is a physiological inhibitor of insulin
receptor activation and thus associated with insulin resis-
tance, metabolic syndrome (MetS) and an increased risk for
T2DM [6,7]. In this context, the role of dendritic cells (DCs)
is intriguing. DCs are antigen-presenting cells that have a
significant role in the pathogenesis of atherosclerosis and
autoimmune diseases [8]. Together with other leukocytes
DCs are involved in low grade inflammation and influence
the atherogenic process by modulating cellular and humoral
immune response. DCs accumulate in the arterial intima
where they contribute to local inflammation and lesion
destabilization [9]. However, their role in early stage of vas-
cular remodeling is still under investigation. It is reported
that diabetes and obesity modulate DC function. Adipokines
released by visceral adipose tissue (VAT), such as chemerin
[10], are reported to recruit circulating DCs and other
immune cells contributing to metaflammation [11–13]. In
our previous work some characteristics of circulating and
monocyte-derived dendritic cells (Mo-DCs) collected from
obese and diabetic postmenopausal women were explored,
in order to find markers of altered immune response before
the onset of any possible cardiovascular event [14]. We
reported that Mo-DCs obtained from circulating precursors
display a defective phenotype compared to controls and
demonstrated a higher ability to adhere to coronary vascular
smooth muscle cells, suggesting that insulin-resistance and
obesity modulate DC function. In this paper, DCs from obese
and T2DM postmenopausal patients were further character-
ized. Fetuin-A and adiponectin were also measured, in order
to assess any difference between T2DM and T2DM-obese
patients. Moreover, the effect of hyperglycaemia on in vitro
immature DCs (iDCs) yield from circulating precursors and
their maturation was assessed.2. Material and methods
2.1. Patients
Fiftytwo post-menopausal women, (to avoid potentially con-
founding factors related to menstrual cycle-related fluctua-
tion in plasma estrogen concentration), were recruited from
the Diabetology, Careggi University Hospital, (AOU-Careggi)
Table 1. Eleven patients were obese with body mass index
(BMI) > 30, seventeen were T2DM obese while ten were only
T2DM. All T2DM subjects were treated with insulin sensitizer
oral drugs, such as metformin or pioglitazone. All patients
have been evaluated for their lipidic and glycaemic profile
(fasting plasma glucose). They had an age of 66.34 ± 8.55 years.
Exclusion criteria included: presence of hepatic, cardiac or
renal insufficiency, cancer, insulin therapy, any previous car-
diovascular event. The control group consisted of 14 age
matched healthy post-menopausal women. For each partici-
pant 3 samples of about 5 ml of fresh peripheral blood in
test-tubes with EDTA were collected. Written consent was
obtained from each participant. The protocol was approved
by the local Ethical Committee (prot. N. 0011762).
2.2. Blood sampling and ex-vivo generation of Mo-DCs.
CD14+ cells were separated performing a positive selection
with CD14 micromagnetic beads by magnetic cell sorting
(MACS) according to the manufacturer’s instructions. DCs
were generated by culture of CD14+ in RPMI 1640 as previously
reported [15].
To assess glucose effect on Mo-DC generation, two proto-
cols were used. (1) iDCs and Mo-DCs were obtained by grow-
ing CD14+ in the presence of increasing D-glucose
concentrations. (2) high glucose effect was only evaluated
on iDC maturation, by growing them in the presence of
33 mM D-glucose during the 24 h-stimulation with 100 nM
LPS. Mannitol was added to the medium to bring total osmo-
lality to a value equivalent to 33 mM glucose.
2.3. Flow cytometry
The following fluorescent monoclonal antibodies were used
for flow cytometry analysis of iDCs and Mo-DCs: CD80-
isothiocyanate (FITC), CD83-phycoerythtrin (PE), CD86-
allophycocyanin (APC), (BD Pharmingen; San Diego, CA).
Isotype-matched antibodies were used as negative control.
Table 1 – Clinical characteristics of enrolled patients. Mean ± SD or median ± range. *P < 0.05, , ***P < 0.001 vs obese. ^P < 0.001
vs T2DM. P < 0.01, P < 0.001 vs T2DM and obese.
Variables Healthy Obese (n = 11) T2DM (n = 10) T2DM Obese (n = 17)
Age (years) 65,40 ± 8,23 64,36 ± 8,23 69,20 ± 7,70 65,94 ± 9,25
BMI (Kg/m2) 24,20 ± 4,50 37,54 ± 6,81 26,33 ± 3,49***  33,52 ± 4,02
Total cholesterol (mg/dL) 160,00±20,00 219,22 ± 35,72 186,95 ± 32,00 176,18 ± 26,37*
HbA1c (%) 4,60 ± 0,80 5,63 ± 0,19^ 7,56 ± 0,66 7,24 ± 0,56
HDL-C (mg/dL) 50,00± 15,01 61,22 ± 14,94 58,60 ± 10,61 54,53 ± 12,66
LDL-c (mg/dL) 95,20 ± 15,00 135,97 ± 35,98 107,84 ± 33,07 91,95 ± 25,51***
Glycemia (mg/dL) 90,10 ± 5,00 103 [62–128] 186 [104–240]* 123 [89–242]*
Triglycerides (mg/dL) 84,00 ± 10,00 108 [77–181] 81 [69–171] 141 [75–223]
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Usa, San Diego, CA) was used to exclude dead cells from anal-
ysis. For lymphocyte proliferation assay the following mono-
clonal antibodies were used: anti-CD3- PerCP-Cy 5.5, CD4-PE
and -CD8-APC. After selection of CD3+CD4+ or CD3+CD8+ sub-
sets, the shift of CFSE-FITC stained proliferating cells versus
the unstimulated lymphocytes was compared
2.4. Isolation of human peripheral blood mononuclear
cells and mixed lymphocyte reaction (CFSE)
Allogeneic peripheral blood mononuclear cells (PBMCs) were
seeded in RPMI 1640 and 10% FBS and monocytes were let
to adhere 45 min. Suspended leukocytes were collected, cen-
trifuged at 1200 rpm for 10 min and used for mixed leucocyte
proliferation with Mo-DC. Briefly, 107 lymphocytes were
stained with 5 lM of CFSE (Molecular Probes, Eugene, Oregon,
USA) according to manufacturer instructions. Stained lym-
phocytes seeded into black 96-well plates at 2x105 cells/well
and 4  104 Mo-DCs/well were added to each well and incu-
bated for 5 days at 37 C in a humidified chamber in air and
5% CO2. Lymphocytes treated with phytohemagglutinin 5lg/
ml (PHA) or untreated were used as positive and negative con-
trol of proliferation, respectively. At the end of 5 days of
mixed reaction, cells were harvested and stained for flow
cytometry analysis of lymphocyte proliferation [15].
2.5. Real time PCR
RNA was isolated from Mo-DC obtained from patients with
TRI Reagent (Sigma–Aldrich, Milan, Italy) and quantified
spectroscopically with NanoDrop (Thermo-fisher scientific,
Waltham, Massachusetts, USA). One lg of RNA was retro-
transcribed using Prime Script RT reagent Kit with gDNA
eraser (Takara, Otsu, Japan) and 50 ng of cDNAwere amplified
with specific primers described below. For CD11c mRNA fw:
CCAGTGTGGCTACAGCACTGGTGCC and rev: TGGGTGAGC-
TGGGTGGGGCCC; CD18 fw: CTGTCTGAGGACTCCAG-
CAATGTGG and rev: CACCTGGAAGGTGATCGGGACATTGAT;
DC-SIGN (CD209) fw: CCAGCAGATACATGGCCACAAGAGC and
rev: CTGCAGCTTTAAGCTGGGTCAGGTTCT; PCR amplification
was carried out as using SYBR Premix Ex Taq (Takara, Otsu,
Japan) according to manufacturer instructions on Rotorgene
RG-3000A cycle system (Qiagen, Germany) platform.. PCRamplification of 18 s rRNA was used as the normalizer. Real-
time PCR assays were performed using the Rotorgene RG-
3000A cycle system (Qiagen, Germany). PCR amplification of
18 s rRNA was used as the normalizer fw:
ATTAAGGGTGTGGGCCGAAG and rev: GGTGATCACACGTTC-
CACCT. The cycle was set at 95 C for 5 s followed by 30 s at
60 C and repeated 40 times.
2.6. ELISA
One ml of fresh peripheral blood was collected in test-tubes
with EDTA and serum harvested for fetuin-A and adiponectin
measurement by means commercially available enzyme-
linked immunosorbent assay kits (R&D System).
2.7. Statistical evaluation
Parametric data were reported as means ± SEM and differ-
ences between groups were tested with ANOVA test (followed
by Bonferroni’s and Dunnett’s Multiple Comparison Test) as
appropriate. Non-parametric measures were reported as
median ± range and differences among groups were tested
with Kruskal Wallis test. Association among non-parametric
variables were tested with Spearman correlation. Alpha value
was set at 0.05.3. Results
3.1. Functional characterization of Mo-DCs of obese and
T2DM patients
We previously demonstrated that DC precursors isolated form
T2DM obese patients displayed less capability to trans-
differentiate into mature monocyte-derived DCs (Mo-DCs).
To confirm their phenotype, their ability to stimulate allo-
genic lymphocytes was assessed. Mo-DCs obtained from
T2DM obese patients were significantly less able to induce
cytotoxic lymphocytes CD8+ proliferation, compared to
control- and obese-derived Mo-DCs, in accord to phenotypic
analysis [14]. A defective function, although not statistically
significant, was observed for Mo-DC obtained from T2DM-
not obese patients. Moreover, no differences were observed
for CD4+ proliferation (Fig. 1).
Fig. 2 – Real-time PCR for CD11c, CD18 and DC-SIGN/CD209
mRNA expression. Total RNA was isolated from Mo-DCs of
obese, T2DM, and T2DM + obese patients and control
subjects. Data are expressed as relative expression vs
control healthy subjects (C). Means ± SEM, n = 8; *P < 0.05,
**P < 0.01 vs control healthy subjects (C). ^P < 0.05 vs obese;
#P < 0.05 vs T2DM.
Fig. 1 – Mixed lymphocyte reaction (CFSE). Allogeneic
lymphocytes were co-cultured with Mo-DCs obtained from
obese, T2DM and T2DM + obese patients and control
subjects. Their proliferation was assessed by flow
cytometry. Means ± SEM, n = 9; ^P < 0.01 vs obese; *P < 0.05
vs control healthy subjects (C).
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derived Mo-DCs
Obese and T2DM patients are characterized by low-grade
inflammation with increased adhesion molecule at vascular
levels which mediate leucocyte recruitment. It was demon-
strated that Mo-DCs isolated from T2DM obese patients dis-
played higher ability to adhere to human coronary vascular
smooth muscle cells (CASMC) [14]. Consistently, Mo-DCs iso-
lated from healthy subjects significantly increased their adhe-
sion to CASMC treated with IFNɣ and TNFa, compared to
control-untreated CASMC [15]. We then investigated mRNA
expression of counter-receptors of vascular adhesion mole-
cules, in Mo-DCs obtained from enrolled patients. As reported
in Fig. 2, CD11c, CD18 and DC-SIGN/CD209 mRNA expression
was significantly higher in T2DM obese patients than obesealone, T2DM alone or control DCs, supporting the hypothesis
that low grade inflammation affects DC phenotype at vascu-
lar level.
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differentiation and iDC maturation
Since Mo-DCs obtained from T2DM obese patients display
defects on phenotype and function compared to obese and
control ones, we investigated the effect of high D-glucose
concentrations on CD14+ trans-differentiation into iDC and
then their maturation (Mo-DCs) in response to LPS. For this
purpose, CD14+ isolated from healthy subjects were grown
in the presence of increasing concentration of D-glucose
and let to obtain Mo-DCs. We used 33 mM mannitol as a
high-osmolarity control treatment. Flow cytometry analysis
showed that 33 mM D-glucose significantly impaired Mo-
DCs yield, although did not affect CD14+ trans-
differentiation into iDCs, demonstrated by a significant
decrease of cells expressing CD83 (Fig. 3A). This impairment
was not due to high osmolarity, since 33 mM mannitol was
devoid of any effect. However, hyperglycaemia did not impair
iDC maturation into Mo-DCs, when they were obtained from
CD14+ in normoglycaemic conditions and then were let to
maturate into Mo-DCs in the presence of 33 mM D-glucose
(Fig. 3B).
3.4. Fetuin-A and adiponectin expression
Fetuin-A is a multifunctional plasma protein associated with
insulin resistance. Its plasma levels are higher in T2DM orFig. 3 – Effect of high D-glucose on CD14+ trans-differentiation (
obtained from CD14+ grown for 7 days in the presence of increa
grown in standard mediumwere then let to maturate into Mo-DC
n = 7; Close to each bar graph: representative histograms. *P < 0
glucose; Man: D-mannitol.obese patients, but its role in the pathogenesis of diabetes
and obesity is still discussed [16,17]. We then characterized
fetuin-A and adiponectin levels in enrolled patients. As
reported in Fig. 4A, adiponectin levels were significantly lower
in T2DM obese patients compared to controls (p
value = 0.0083). Consistently, T2DM obese patients displayed
significant higher concentration of fetuin-A, compared to
controls (p value = 0.0457, Fig. 4B). No differences were found
in fetuin-A when patients were divided into 2 subgroups,
according to HbA1c: T2DM obese with HbA1c < 7.0 and
T2DM obese with HbA1c > 7.0 (data not shown). A negative
correlation between fetuin-A and adiponectin was found in
all population (r = -0.492p value = 0.00108, Fig. 4C), and in pop-
ulation stratified according to the presence/absence of T2DM
and obesity (Fig. 4D). A negative (r = -0.416p value = 0.0199)
and positive significant correlation (r = 0.549p value = 0.00139)
with BMI was obtained for adiponectin and fetuin-A, respec-
tively (Fig. 4E and F).
4. Discussion
T2DM is as a chronic, low-grade inflammatory disease caused
by long-term immune system imbalance, and is often associ-
ated with obesity or MetS. Increasing evidences support the
role of autoimmunity and adaptive immune system in the
pathogenesis of T2DM and its vascular complications [18].
The impact of DCs on the initiation and progression ofA) and iDC maturation (B) into Mo-DCs. (A) Mo-DCs were
sing D-glucose concentrations. (B) iDC obtained from CD14+
s in the presence of 33 mMD-glucose for 24 h. Means ± SEM,
.05 vs Mo-DC. iDC: immature DC; MoDC: mature DCs; glu: D-
Fig. 4 – Adiponectin (A) and Fetuin-A (B) levels in controls and enrolled patients. (C) Spearman rank correlation between
fetuin-A and adiponectin in all population (r = 0.492p value = 0.00108, (C) and in population stratified according to the
presence/absence of T2DM ± obesity (D). Adiponectin (E) and Fetuin-A (F) correlation with BMI in T2DM ± obese patients.
Spearman’s rank correlation coefficient r = 0.416p value = 0.0199 for adiponectin and r = 0.549 with p value = 0.00139 for
fetuin-A.
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levels are reported to contribute to vascular remodeling, and
among them conventional DCs (cDCs) seem to have a pivotal
role, although plasmacytoid DCs (pDCs) can be found in
atherosclerotic lesions in apolipoprotein E–deficient (Apoe/)
and low-density lipoprotein receptor-deficient (Ldlr/) mice
[19,20]. In human tissue, cDCs, corresponding to the two sub-
sets of myeloid DC as previously described [21], and CD123+
pDC numbers were increased in unstable compared with
stable lesions, mainly localizing to the shoulder region of pla-
ques [22]. In patients with peripheral artery disease Kret-
zschmar and co-authors (2015) [23] have reported a decrease
in circulating DC precursors, suggesting an increase of their
accumulation into vessel lesions. Despite these data, it is
unclear the pathogenetic role of DCs in the initiation of vas-
cular remodeling associated with high risk CVD. For this pur-
pose, we selected post-menopausal obese woman with or
without diabetes or patients with diabetes alone without
any previous major CV event, in order to characterize DC
function. We previously reported that Mo-DCs obtained from
T2DM obese post-menopausal woman display a defective
phenotype compared to obese and control ones. Present
paper demonstrates the latter DC population being less able
to stimulate CD8+ cytotoxic T lymphocytes, compared to
Mo-DCs obtained from obese or T2DM and control ones.
These data are a new observation and reflect the immune
state of these patients, in which DC dysfunction may con-
tribute to an increased susceptibility to infections and to
higher risk of CVD [24,25]. It is known that obesity and
T2DM diseases share T cell alterations that may contribute
to their additional metabolic disturbances. In T2DM and obe-
sity there is a shift of CD4+T cell subsets toward a proinflam-
matory phenotype, such as CD4+ Th1 and Th17 and a
regulatory T cells (Treg) [26]. Proinflammatory Th1 cells pro-
ducing IFN-c are correlated with adiposity [27] and patients
with diabetes display an increase of CD4+CD28null T lympho-
cytes, a subpopulation exerting direct cytolytic and proapop-
totic effects on endothelial cells and vascular smooth muscle
cells [28,29].
According to published data, our present paper strength-
ens metanflammation in enrolled population, since Mo-DCs
obtained from T2DM obese patients express higher mRNA
levels of integrins, such as CD18 and CD11c, compared to
obese or T2DM ones, which may modulate their adhesion to
vascular wall cells, as previously published [14]. Among inte-
grins binding vascular adhesion molecules, beta2 integrin
CR4 (CD11c/CD18) seems to be important for a strong Mo-
DC adhesion to fibrinogen in order to mediate their trans-
endothelial migration [30]. Retention of leukocytes to vascular
wall is involved in the worsening of inflammatory condition,
leading to the progression and complication of vascular
remodeling. Consistently, hyperglycaemia up-regulates adhe-
sion molecule expression [31] modulating immune cells
recruitment, as reported in subcutaneous abdominal adipose
tissue of obese women without metabolic complications [32].
Despite this, the effect of hyperglycaemia on DC phenotype
and function is still controversial. Present data show defective
Mo-DCs yield when hyperglycaemia was applied to theircirculating precursors, CD14+, during all their culture condi-
tions (7 days). Nevertheless, when iDC were obtained in nor-
moglycemic condition and then were let to maturate in the
presence of high D-glucose for 24 h, Mo-DCs yield was not
impaired. This result is apparently in contrast to that of Lu
et al (2013) [33], who reported an increase of DC yield in
response to high D-glucose concentration. However, their
experimental design was different, since they applied high
D-glucose to CD14+ after a-5 days of normoglycemic condi-
tion, without adding LPS for their maturation. More recently,
it was reported that hyperglycemic sera from T2DM patients
impaired DC differentiation through ROS production [34],
highlighting DC dysfunction in these patients which may be
responsible to their defective immune response.
Circulating fetuin-A and adiponectin were also measured
in enrolled patients. Fetuin-A is an endogenous inhibitor of
insulin receptor and epidemiological and clinical studies
reported that high plasma fetuin-A levels are associated with
insulin resistance (IR), MetS and risk of T2DM [16,35], the lat-
ter seemed more evident in women than in men [36]. In con-
trast adiponectin protects against insulin resistance/diabetes
and atherosclerosis and its plasma levels decrease in T2DM or
obese patients [37]. Our results show an inverse correlation
between adiponectin and fetuin-A in enrolled patients, being
fetuin-A significantly higher and adiponectin significantly
lower in T2DM obese patients compared to healthy subjects.
These results extend previous cross-sectional study in which
fetuin-A and adiponectin were measured in a new diagnosed
T2DM patients (either male and female), younger than
patients in our study and with a BMI > 25 [38]. Interestingly,
our present data showed that fetuin-A and adiponectin levels
were not significantly different in T2DM patients compared to
controls. This result, apparently in contrast with previous
published, could be explained by pharmacological therapy.
All T2DM enrolled woman were indeed treated with insulin
sensitizers drugs, such as metformin or pioglitazone, which
were reported to modulate adiponectin and/or fetuin in obese
and/or T2DM patients [39–42], whose mechanisms, still under
investigation, are not likely dependent on improved glycemic
control alone.
5. Conclusions
All together these data confirm a dysfunction of Mo-DCs
obtained from circulating precursors of T2DM obese post-
menopausal woman without any clinical CV event docu-
mented. The association of obesity with diabetes seems to
worsen DC phenotype and function with potentially greater
ability to mediate inflammation. Our data underline the
importance of the multiple CV risk factors coexistence in a
patient. Pharmacological treatment is almost certainly able
to revert fetuin-A and adiponectin dysregulation in post-
menopausal T2DM woman, while is not in T2DM obese ones.
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